OPINION Array comparative genomic hybridization: its role in preimplantation genetic diagnosis
INTRODUCTION
Embryo assessment is a crucial component to the clinical success of IVF techniques. Selection of the most competent embryo(s) for transfer is generally based on morphological criteria, with the highest implantation rates observed with the use of optimal morphologic and developmental characteristics [1] . Although this information provides an important contribution to the prediction of reproductive competence and improvement of pregnancy rates, conventional embryo selection methodologies are not sufficient. In fact, many women fail to achieve a pregnancy even after transfer of goodquality embryos. These couples may undergo multiple unsuccessful IVF cycles and so often seek further options to improve their chances of a positive outcome.
Investigators began exploring possible mechanisms that could result in the failure of morphologically normal embryos to implant and develop into healthy infants. One of the presumed causes is that such morphologically normal embryos show an abnormal number of chromosomes (aneuploidies) [2] . A recent study [3 && ], assessing the correlation between blastocyst morphology and chromosomal status, demonstrated that morphologic analysis of blastocysts cannot be relied on to ensure transfer of chromosomally normal embryos, because a significant proportion of aneuploid embryos are capable of achieving the highest morphologic scores, and some euploid embryos are of poor morphology. Aneuploidy affected more than one-half of the blastocysts analyzed in this study.
Chromosomal aneuploidy is a recognized significant contributing factor in implantation failure and spontaneous miscarriage [4] . The prevalence of aneuploidy in live births and pregnancy losses rises dramatically with age and parallels the natural decline in fertility [5] . The outcomes for the pregnancy attempts can vary from implantation failure, early-stage to late-stage miscarriage or abnormal live births, depending on the chromosomes involved.
Preimplantation genetic diagnosis (PGD) for aneuploidy screening of embryos derived from subfertile patients undergoing IVF, also named preimplantation genetic screening (PGS) enables the assessment of the numerical chromosomal constitution of embryos before transfer. PGS offers IVF couples an additional selection tool over simple developmental quality for choosing the best embryo for transfer [6] . It aims to enhance embryo selection, identifying and selecting for transfer chromosomally normal (euploid) embryos in order to increase the implantation and ongoing pregnancy rate for IVF patients, reduce the time to pregnancy, lower the incidence for miscarriage and reduce the risk of having a baby with an aneuploidy condition [7] .
Historically, aneuploid screening of embryos has involved the use of fluorescence in situ hybridization (FISH) technique, in which only a limited subset of chromosomes can be analyzed (five, nine or 12 chromosomes), to detect those aneuploidies that cause lack of implantation or can result in a miscarriage early in pregnancy or most commonly observed after birth [7] . This panel of probes has the potential of detecting over 70% of the aneuploidies found in spontaneous abortions.
Initial PGS studies using FISH demonstrated a high prevalence of aneuploidy in human embryos [7] . Reasonably, this provided an apparent opportunity to improve outcomes by screening embryos for aneuploidy before transfer. Unfortunately, clinical results have been disappointing. A large number of prospective, randomized clinical trials (RCTs) [8] have consistently failed to show any improvement in delivery rates using FISH-based PGS on cleavage-stage embryos. As a consequence of these studies, several clinics no longer use this methodology.
There are many possible reasons why the above clinical studies failed to deliver the expected improvements in IVF outcome. Putative explanations for this poor clinical performance could be attributed to an incomplete understanding of important aspects of embryo biology, such as embryonic chromosomal mosaicism that is present on day 3 of development (i.e. the tested blastomere is not representative of the whole embryo) [9] , or self-correction of aneuploidy within the embryo, which may decrease the chances of a live birth by prematurely labeling an embryo as abnormal. Indeed, high levels of chromosomal mosaicism have been observed in blastomeres from cleavagestage embryos [9] . Alternatively, it has been argued that inadequate cytogenetic methods may have led to reduced diagnostic accuracy and elimination of any potential benefit of screening [10, 11] . In fact, all prior clinical trials using PGS for IVF have used FISH, which screens for a minority of chromosomes (less than half of the human chromosomal complement), and may result in the transfer of reproductively incompetent embryos with aneuploidy for chromosomes not analyzed. However, these chromosomes are not necessarily the most relevant for early embryos. Thus, the limitations of the FISH technology could have compromised the results of these studies. Therefore, the present work on PGS is exploring the use of new technologies that allow for more comprehensive screening of chromosomes.
DETECTION OF CHROMOSOMAL ANEUPLOIDY ON EMBRYOS BY ARRAY COMPARATIVE GENOMIC HYBRIDIZATION
Despite the fact that FISH-based PGS has not succeeded in improving clinical outcomes, the concept remains valid. Embryos that are aneuploid should principally fail to implant, and those that do implant will generally result in pregnancy loss or in live births of children with chromosomal aberrations.
The development of novel technologies for comprehensive chromosome screening of human
KEY POINTS
A high rate of embryos produced in vitro present chromosomal abnormalities and have reduced potential for achieving a viable pregnancy. aCGH allows for comprehensive aneuploidy screening of embryos, with the aim to improve IVF outcomes.
Initial studies on clinical application of this technology have documented improved pregnancy outcomes following transfer of screened embryos.
The optimal stage of preimplantation development at which PGS should be performed still remains to be determined.
Further evidence is still required to establish whether PGS results in enhanced live birth rate.
genome provides the opportunity to more accurately assess the reproductive potential of embryos, overcoming the technical difficulties that beset earlier PGS studies.
Some of the most promising progress toward developing a comprehensive 24 chromosome analysis method has been made possible through the combination of whole genome amplification (WGA), a protocol able to amplify the entire genome from a single cell, and array comparative genomic hybridization (aCGH) [12] .
aCGH is a technique that uses microarray technology and allows for comprehensive aneuploidy screening through its ability to indirectly detect imbalances in any of the 24 chromosomes. This approach involves a competitive hybridization, to genomic probes of known sequence immobilized on a glass microarray, of two differentially labeled DNA samples, one derived from the embryo after a WGA reaction (test DNA) and the other from a euploid DNA sample (reference DNA). Software analysis of the scanned microarray is used to detect gains (trisomies) and losses (monosomies). This method has a high resolution, the analysis is fully automated and the whole procedure (WGA and aCGH analysis) requires up to 24 h to complete.
aCGH techniques have been recently introduced into current routine PGS laboratory practices, allowing screening of the entire chromosome complement, rather than the limited chromosome assessment achievable by FISH [12, 13
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& , 15, 16] . This assay may provide a more comprehensive and accurate approach to improve IVF outcomes.
The first data from comprehensive aneuploidy screening showed that aneuploidies may occur in preimplantation embryos in any of the 24 chromosomes indicating that aneuploidy screening of all chromosomes is necessary to determine whether an embryo is chromosomally normal [ 
STAGES FOR ANALYSIS: POLAR BODIES, CLEAVAGE STAGE AND BLASTOCYST?
There are several stages during preimplantation development at which comprehensive aneuploidy screening can be performed, including polar bodies from the oocyte and zygote, a single blastomere from a cleavage-stage embryo and a group of cells from the trophectoderm at the blastocyst stage [24] . Each approach has a variety of theoretical limitations that are both technical and biological in nature [25] .
PGS was historically carried out by testing single blastomeres removed from day 3 cleavage-stage embryos. However, 24 chromosomes aneuploidy screening performed at this stage might still be compromised by the degree of mosaicism observed in such embryos that could have a negative impact on clinical outcome of PGS because the tested blastomeres may not be representative for the whole embryo. Nevertheless, in recent studies [13
&&
,26
& ], nontransferred chromosomally abnormal embryos that developed to blastocyst stage, diagnosed by aCGH performed at cleavage stage, were rebiopsied at day 6 and reanalyzed in order to ascertain whether the tested blastomeres were representative for the whole embryo. Despite high levels of mosaicism found (45%), all day 3 aneuploid embryos followed up were again diagnosed as abnormal after reanalysis on trophectoderm cells, confirming at the end the previous results regardless of the actual abnormal genotype. In the above studies, aCGH analysis on single blastomeres has demonstrated an accurate tool for aneuploidy detection and may assist in identifying abnormal embryos even at cleavage stage.
Several groups are currently concentrating PGS studies on testing both the first and second polar body [27, 28 && ]. This approach would avoid the problem related with chromosomal mosaicism occurring on embryos at cleavage stage. Analysis of polar bodies may also be preferred to blastomere biopsy as it would be potentially minimally invasive and less damaging (although there are no studies demonstrating it), as the polar body is a discarded byproduct of maturation and has no further role in embryo development, leaving the oocyte uncompromised. However, this technique is labour intensive, because all oocytes have to be tested despite the fact that a significant number will not fertilize or will fail to form normal embryos suitable for transfer. Furthermore, aneuploidy detection in first and second polar body will detect the majority of the aneuploidies that arise from the maternal genome, which is particularly relevant for patients of advanced maternal age, but this technique ignores the possible contribution from the paternal genome and any aneuploidies that may arise during aberrant mitotic divisions.
Another challenge associated with polar body chromosome screening is related to making the decision to discard oocytes with aneuploid polar bodies or based on aneuploidy in the first polar body alone [29, 30] . In fact, among the possible abnormal chromatids segregation, there are specific combinations involving reciprocal aneuploid polar bodies, producing chromosomally normal zygotes. In particular, when the first polar body acquired only one chromatid from meiosis I and the 2PB acquired the corresponding extra chromatid from meiosis II, the resulting zygote could be euploid. Similarly, an extra chromatid in the first polar body and a corresponding missing chromatid in the 2PB could also lead to a euploid zygote.
A similar phenomenon was reported in the preclinical study evaluating the utility of polar body aCGH conducted by the European Society of Human Reproduction and Embryology (ESHRE) PGS Task Force in which data indicated that 4% of the oocyte/polar body pairs resulted displayed euploidy in the resulting zygotes despite aneuploidy in the corresponding polar bodies [28 && ]. Another study reported this aneuploidy compensation at a frequency of 1.7% [21] . Recently, the first evidence supporting the reproductive potential of oocytes with reciprocal aneuploid polar bodies was reported, demonstrating their ability to produce chromosomally normal children [31 & ]. Considering the above findings, the suitability of discarding an oocyte based solely on the observation of reciprocal aneuploidy in the polar bodies, or based on identification of aneuploidy in the first polar body alone, could be questioned [29, 30] .
PGS by trophectoderm biopsy on embryos at the blastocyst stage of development (day 5 or 6 after fertilization) has been proposed as another alternative [21, 22] . Biopsy at this stage has the advantage of allowing more cells to be sampled ( five cells), making comprehensive aneuploidy screening more robust. It also removes trophectoderm cells, leaving the integrity of the inner cell mass that goes on to form the fetus intact. Current IVF cycle management involves the use of two different strategies: day 5 blastocyst biopsy and embryo transfer on day 6; or day 5-6 biopsy followed by blastocyst vitrification and subsequent transfer in a freeze/ thaw cycle.
From the clinical perspective, there has been increasing interest in screening blastocyst-stage embryos for chromosomal abnormalities, with a view to detecting and preferentially transferring euploid normal embryos during IVF cycles. Preliminary clinical data suggest that the use of blastocyst biopsy combined with comprehensive chromosome analysis by aCGH may represent the optimal approach for PGS, delivering the expected boost to assisted reproduction results initially anticipated for aneuploidy diagnosis [20 && ,21-23,32 & ]. However, more data are still necessary concerning the accuracy and validation of aCGH on blastocyst biopsies. In particular, the impact of mosaicism on testing at the blastocyst stage remains to be better defined, although a recent study demonstrated that aCGH analysis of blastomeres obtained from trophectoderm biopsy is an excellent predictor of the inner cell mass karyotype [33] .
Although numerous considerations for the efficacy of using a specific stage of biopsy for PGS exist, one of the most important may be the impact that the procedure has on the reproductive potential of the embryo. In fact, amongst the most critical questions surrounding PGS are the risks associated with oocyte/embryo biopsy itself, and whether biopsy is safest if performed on polar bodies, or on embryos at the cleavage or blastocyst stage.
Recently, a prospective, blinded, clinical study to accurately assess the negative and positive predictive values of blastomere biopsy from embryos at cleavage stage and trophectoderm biopsy was reported [18 && ]. This study involved randomization of the two best embryos so that one was biopsied (case) and the other was not (control), and subsequent paired analysis of outcomes within each two embryo transfer. Interestingly, the results indicated that embryo biopsy at the cleavage stage significantly reduces the implantation potential of the embryo. In contrast, the implantation rate of biopsied and nonbiopsied blastocysts was equivalent, indicating that trophectoderm biopsy of blastocysts does not adversely impact embryonic reproductive potential. Possible explanations as to why blastocyst biopsy is well tolerated when cleavage stage biopsy is not, include the removal of a smaller proportion of the embryo and better embryonic tolerance of manipulation after genomic activation.
Similar studies of the impact of polar body biopsy have yet to be performed. Once available, these data will be helpful in characterizing the safety and optimal stage of biopsy for comprehensive aneuploidy screening. & ], further data are required to establish whether PGS results in enhanced live birth rate, and if this is the case, to identify which patients may benefit from the procedure [10, 34] . The only effective way to resolve this debate on PGS usefulness is to perform well designed and well executed RCTs. The design of further studies should include an adequate randomization protocol with a clear stratification concerning the indications to perform PGS, the replacement of the same number of embryos in both study and control groups and the healthy live birth rate per treatment cycle as the main outcome measure.
RANDOMIZED CONTROLLED TRIALS ON PREIMPLANTATION GENETIC SCREENING BY ARRAY COMPARATIVE GENOMIC HYBRIDIZATION
Several RCTs performed by aCGH technique, at different cell biopsy stage and categories of patients, are currently ongoing to assess clinical efficacy of PGS. Most of these studies (www.clinicaltrials. gov, ID numbers, NCT01194531, NCT01219283 and NCT01332643, and www.controlledtrials.com, ID number ISRCTN37972669, ISRCTN41698043) involve evaluation of aCGH or single nucleotide polymorphism (SNP) array technology on embryos at cleavage or blastocyst stage for advanced maternal age (AMA) and repeated implantation failure (RIF) indication. In contrast, the ESHRE PGS Task Force has set up a multicenter RCT (www.clinicaltrials. gov, ID number NCT01532284) to assess the utility of polar body aCGH for patients of AMA [27, 28 && ]. ]. For this reason, whether the accuracy achievable using aCGH for PGS is good enough to improve the patient outcome remains debatable and has still to be demonstrated by means of randomized trial [8, 35] .
ARGUMENTS AGAINST PREIMPLANTATION GENETIC SCREENING USEFULNESS
A sound argument against embryo selection in principle has recently been published [36] , based on accumulating evidence that potentially all embryos can now be cryopreserved and transferred in subsequent frozen replacement cycles without impairing pregnancy rates compared with when selection is used. However, regardless of the effectiveness of aneuploidy screening in delivering acceptable live birth rates over a shorter time period, the application of an expensive technology for embryo selection to improve IVF success rates may be unnecessary with the development of highly effective and efficient cryopreservation protocols such as vitrification [36] . Other authors [35] believe that in such a scenario, the use of a selection method cannot increase (but could decrease) the live birth rate per stimulated IVF cycle when all embryos are serially transferred (albeit potentially reducing the time to first delivery). Indeed, there may be an argument for vitrification of all embryos without fresh transfers, considering potentially superior perinatal outcome of births resulting from transfer of thawed blastocysts [37] . Therefore, these authors [35, 36] suggest that vitrification and serial transfer without testing are likely to give patients the best chance for a successful pregnancy, and avoid the use of an expensive technology.
PREIMPLANTATION GENETIC DIAGNOSIS FOR CHROMOSOMAL TRANSLOCATION USING ARRAY COMPARATIVE GENOMIC HYBRIDIZATION
aCGH is now used extensively worldwide, not only for whole chromosome aneuploidy screening but also for PGD of segmental chromosome imbalance in couples carrying balanced reciprocal or Robertsonian translocations [13
. This approach represents a valuable alternative to the FISH-based and PCR-based PGD protocols. In contrast to the above-mentioned methods, aCGH allows screening for all aneuploidies in addition to the unbalanced derivatives associated with the specific translocation. This technique, allowing a complete chromosome analysis of the embryo, avoids transfer of reproductively incompetent embryos with aneuploidy for chromosomes not analyzed, by providing information regarding not only the chromosomes involved in the translocation.
Another advantage on the use of aCGH technology is that it does not require preclinical validation before each IVF cycle that is necessary for FISH or PCRbased methods of translocation screening. This spares couples the cost of workup testing, also allowing a rapid starting of the IVF treatments. In fact, a PGD cycle can be scheduled directly on the day of biopsy, based on the number of embryos available for biopsy.
Finally, aCGH can also be used for more complex karyotypes, with multiple rearrangements, in which FISH testing is generally very complicated.
The first [13 && ] clinical application of aCGH on PGD for chromosomal translocation, involving a large cohort of embryos tested, reported over 70% clinical pregnancy rate, more than double the rate that was reported using earlier, FISH-based, techniques. Data obtained demonstrated that aCGH can detect chromosome imbalances in embryos, also providing the added benefit of simultaneous aneuploidy screening of all 24 chromosomes. The importance of performing aneuploidy screening in parallel with the diagnosis of chromosomal imbalances in embryos derived from translocation carriers was demonstrated in this study by the prevalence of aneuploidy in embryos that were diagnosed normal or balanced for the chromosomes involved in the translocation.
In fact, 27 .3% of the embryos tested were diagnosed as normal balanced for translocation, but also showed aneuploidy of chromosomes unrelated to the translocation. These embryos would have been selected for transfer if only translocation screening had been performed.
A number of comprehensive chromosome screening methods have now been applied to evaluating embryos from translocation carrier patients, including aCGH with a resolution of 2. 
CONCLUSION
Despite the failure of cleavage-stage FISH-based PGS in improving IVF clinical outcomes for infertile patients, the introduction of new aCGH-based comprehensive chromosome screening technologies holds great promise for achieving the expected benefit, by selecting the most competent embryo(s) for transfer. However, more evidence still needs to be obtained before its clinical use on routine basis. Results from ongoing RCTs will provide the data needed to accept or reject the clinical utility of aCGH methodology, helping to define the future of chromosome screening in the IVF setting.
